[PDF][PDF] MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
J clin oncol, 2017•sbmastologia.com.br
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as
monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–
positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast
cancer previously treated with endocrine therapy.
monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–
positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast
cancer previously treated with endocrine therapy.
Purpose
Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy.
sbmastologia.com.br